Welcome to our dedicated page for HEMOGENYX PHARMA NEW news (Ticker: HOPHD), a resource for investors and traders seeking the latest updates and insights on HEMOGENYX PHARMA NEW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HEMOGENYX PHARMA NEW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HEMOGENYX PHARMA NEW's position in the market.
Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £340,000 through a placing of 100,000 new ordinary shares at 340p per share. The institutional investor participating in the placing has also received 50,000 warrants, exercisable at 500p each from March 1, 2025, for a 12-month period.
The proceeds will fund the clinical trial of HG-CT-1, the company's lead asset targeting relapsed/refractory acute myeloid leukemia (AML) in adults. The first patient is currently being evaluated for trial inclusion. Trading of the new shares on the London Stock Exchange's Main Market is expected around January 15, 2025.
Following the admission, the company's enlarged issued share capital will comprise 3,604,539 ordinary shares, with no shares held in treasury. The new shares will rank equally with existing ordinary shares.
